benphothiamine has been researched along with Alloxan Diabetes in 16 studies
benfotiamine : A thioester that is a synthetic analogue of thiamine obtained by acylative cleavage of the thiazole ring and O-phospohorylation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fenofibrate normalizes the altered lipid profile in diabetic rats, whereas benfotiamine treatment has no effect on lipid alteration in diabetic rats." | 1.35 | Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. ( Balakumar, P; Chakkarwar, VA; Singh, M, 2009) |
| "Neuropathic pain was induced by either ligation of left L5/L6 spinal nerves or administration of streptozotocin (50 mg/kg, i." | 1.33 | Benfotiamine relieves inflammatory and neuropathic pain in rats. ( Caram-Salas, NL; Granados-Soto, V; Medina-Santillán, R; Reyes-García, G; Rocha-González, HI; Sánchez-Ramírez, GM; Vidal-Cantú, GC, 2006) |
| "Treatment with thiamine did not significantly affect AGE or cmL levels." | 1.31 | Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats. ( Bitsch, I; Bretzel, RG; Federlin, KF; Geyer, J; Hammes, HP; Köpcke, W; Mavrakis, K; Netzel, M; Sauerland, C; Stracke, H; Werkmann, D, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (62.50) | 29.6817 |
| 2010's | 6 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nacitarhan, C | 1 |
| Minareci, E | 1 |
| Sadan, G | 1 |
| Jung, KH | 1 |
| Lee, JH | 1 |
| Park, JW | 1 |
| Paik, JY | 1 |
| Quach, CH | 1 |
| Lee, EJ | 1 |
| Lee, KH | 1 |
| Balakumar, P | 1 |
| Chakkarwar, VA | 1 |
| Singh, M | 1 |
| Katare, RG | 1 |
| Caporali, A | 1 |
| Oikawa, A | 2 |
| Meloni, M | 2 |
| Emanueli, C | 3 |
| Madeddu, P | 3 |
| Karachalias, N | 3 |
| Babaei-Jadidi, R | 3 |
| Rabbani, N | 1 |
| Thornalley, PJ | 3 |
| Du, Y | 1 |
| Kowluru, A | 1 |
| Kern, TS | 1 |
| Katare, R | 1 |
| Cesselli, D | 1 |
| Beltrami, AP | 1 |
| Avolio, E | 1 |
| Muthukrishnan, D | 1 |
| Munasinghe, PE | 1 |
| Angelini, G | 1 |
| Hammes, HP | 2 |
| Du, X | 1 |
| Edelstein, D | 1 |
| Taguchi, T | 1 |
| Matsumura, T | 1 |
| Ju, Q | 1 |
| Lin, J | 1 |
| Bierhaus, A | 1 |
| Nawroth, P | 1 |
| Hannak, D | 1 |
| Neumaier, M | 1 |
| Bergfeld, R | 1 |
| Giardino, I | 1 |
| Brownlee, M | 1 |
| Ahmed, N | 2 |
| Battah, S | 1 |
| Kupich, C | 1 |
| Ceylan-Isik, AF | 1 |
| Wu, S | 2 |
| Li, Q | 1 |
| Li, SY | 1 |
| Ren, J | 2 |
| Sánchez-Ramírez, GM | 1 |
| Caram-Salas, NL | 1 |
| Rocha-González, HI | 1 |
| Vidal-Cantú, GC | 1 |
| Medina-Santillán, R | 1 |
| Reyes-García, G | 1 |
| Granados-Soto, V | 1 |
| Gadau, S | 1 |
| Van Linthout, S | 1 |
| Graiani, G | 1 |
| Todaro, M | 1 |
| Campesi, I | 1 |
| Invernici, G | 1 |
| Spillmann, F | 1 |
| Ward, K | 1 |
| Stracke, H | 1 |
| Werkmann, D | 1 |
| Mavrakis, K | 1 |
| Bitsch, I | 1 |
| Netzel, M | 1 |
| Geyer, J | 1 |
| Köpcke, W | 1 |
| Sauerland, C | 1 |
| Bretzel, RG | 1 |
| Federlin, KF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy[NCT00565318] | Phase 4 | 86 participants (Anticipated) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 other studies available for benphothiamine and Alloxan Diabetes
| Article | Year |
|---|---|
The effect of benfotiamine on mu-opioid receptor mediated antinociception in experimental diabetes.
Topics: Analgesics; Analgesics, Opioid; Animals; Body Weight; Diabetes Mellitus, Experimental; Fentanyl; For | 2014 |
Annexin V imaging detects diabetes-accelerated apoptosis and monitors the efficacy of benfotiamine treatment in ischemic limbs of mice.
Topics: Animals; Annexin A5; Apoptosis; Cell Line, Tumor; Diabetes Mellitus, Experimental; Hindlimb; Ischemi | 2014 |
Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Chelating Agents; Diabetes Mellitu | 2009 |
Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway.
Topics: Analysis of Variance; Animals; Apoptosis; Blood Flow Velocity; Blotting, Western; Carrier Proteins; | 2010 |
Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes.
Topics: Adjuvants, Immunologic; Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Kidney Glo | 2010 |
PP2A contributes to endothelial death in high glucose: inhibition by benfotiamine.
Topics: Analysis of Variance; Animals; Aorta; Blotting, Western; Cattle; Cell Death; Cells, Cultured; Diabet | 2010 |
Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes.
Topics: Animals; Antigens, CD; Antigens, Ly; Apoptosis; Biomarkers; Blood Glucose; Cell Proliferation; Cell | 2013 |
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.
Topics: Animals; Cattle; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelium | 2003 |
Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine.
Topics: Albuminuria; Animals; Chelating Agents; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dos | 2003 |
[Diabetes mellitus. Retinal lesions should not exist!].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Enzyme Activation; Glycated Hemoglob | 2004 |
High-dose thiamine therapy counters dyslipidemia and advanced glycation of plasma protein in streptozotocin-induced diabetic rats.
Topics: Animals; Blood Glucose; Blood Proteins; Diabetes Complications; Diabetes Mellitus, Experimental; Gly | 2005 |
High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus.
Topics: Adjuvants, Immunologic; Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Rel | 2006 |
Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha.
Topics: Adjuvants, Immunologic; Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus, Experimenta | 2006 |
Benfotiamine relieves inflammatory and neuropathic pain in rats.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Diabetes Mellitus, Experimental; Dose-Respons | 2006 |
Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis.
Topics: Animals; Apoptosis; Blotting, Western; Body Weight; Caspase 3; Caspase Inhibitors; Caspases; Cell Pr | 2006 |
Efficacy of benfotiamine versus thiamine on function and glycation products of peripheral nerves in diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Glycation End Products, Advanced; Glycosyla | 2001 |